Home > Insider Trading > Filing (0000899243-21-010795)

Filing Details

Accession Number:: 0000899243-21-010795
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-09 21:06:49
Reporting Period:: 2021-03-05

Accepted Time:: 2021-03-09 21:06:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1521036	Lantheus Holdings Inc.	LNTH	In Vitro & In Vivo Diagnostic Substances (2835)	352318913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1610676	Anne Mary Heino	C/O Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica MA 01862	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-03-05	27,157	$18.26	711,720	No	4	S	Direct
Common Stock	Acquisiton	2021-03-08	11,464	$19.47	723,184	No	4	J	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	J	Direct

Footnotes

The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2020, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.015 to $18.60, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
As noted in footnote (1) above, on March 5, 2021, the reporting person sold 27,157 shares pursuant to a Rule 10b5-1 trading plan. The reporting person's broker erroneously sold shares based on the original target number of shares under a performance share grant rather than the actual number of shares that vested. The amount reported represents the number of shares reacquired by the broker to reverse the error. The weighted average price for the reacquired shares was $19.4659, reacquired in multiple transactions at prices ranging from $19.295 to $19.56, inclusive. The reporting person undertakes to provide to LNTH, any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares reacquired at each separate price within the ranges set forth in this footnote (3) to this Form 4.